3 stories mentioning SHA:600216Updated 83d ago
Every FINWIRES story that references SHA:600216, newest first.
Zhejiang Medicine (SHA:600216) subsidiary Xincode Bio applied for an initial public offering on the Main Board of the Hong Kong Stock Exchange.The spinoff and listing are subject to regulatory clearances from Chinese and Hong Kong authorities, according to a Tuesday filing with the Shanghai bourse.Shares of the drugmaker were down 3% in recent trade.
Zhejiang Medicine (SHA:600216) posted 2025 attributable net profit of 873.4 million yuan, down 25% from 1.16 billion yuan the previous year.Earnings per share declined to 0.91 yuan from 1.21 yuan, according to a filing with the Shanghai bourse.Operating revenue slid 5.3% year over year to 8.88 billion yuan from 9.38 billion yuan.Shares of the pharmaceutical company were down 3% in recent trade.
Zhejiang Medicine (SHA:600216) plans to spin off its subsidiary, Xinma Biopharmaceutical, for listing on the Hong Kong Stock Exchange, according to a Shanghai bourse filing on Saturday.The Chinese drugmaker's shares dropped less than 4% on Monday.
